Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Detection of DNA adduct γ-OHPdG in circulating tumor cells (CTCs) and its use as a prognostic biomarker in patients with hepatocellular carcinoma (HCC).
Authors
Aiwu Ruth He
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC;
Aiwu Ruth He , Fung-Lung Chung , Monika Aggarwal , Zizhao Zhu , Sophie Gould , Kevin Zhang , Mark Kuo , Peter Johnson , Samira Beheshtian , Laura Kuhlman , Zijun Zhao , Hongbin Fang , Bhaskar Kallakury , Karen Creswell , Alexander Kroemer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Translational Research
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 594)
DOI
10.1200/JCO.2023.41.4_suppl.594
Abstract #
594
Poster Bd #
F6
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Agrin as a prognostic biomarker in hepatocellular carcinoma.
First Author: Ankita Kapoor
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Plasma hPG80 (circulating progastrin) as a novel prognostic biomarker for hepatocellular carcinoma at early to intermediate stages (BCLC 0 to B).
First Author: Alexandre Prieur
Poster
2021 ASCO Annual Meeting
Prognostic value of plasma hPG80 (circulating progastrin), alone or in combination with Alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma.
First Author: Alexandre Prieur
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Serologic, radiographic, and tissue-based markers associated with major pathologic response after treatment with neoadjuvant immunotherapy in patients with resectable hepatocellular carcinoma.
First Author: Michael Brian LaPelusa